Psychosis in Parkinson's disease
Identifieur interne :
000939 ( PascalFrancis/Curation );
précédent :
000938;
suivant :
000940
Psychosis in Parkinson's disease
Auteurs : Werner Poewe [
Autriche]
Source :
-
Movement disorders [ 0885-3185 ] ; 2003.
RBID : Pascal:04-0080436
Descripteurs français
English descriptors
Abstract
Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 18 |
|---|
| A06 | | | | @2 6 @3 SUP |
|---|
| A08 | 01 | 1 | ENG | @1 Psychosis in Parkinson's disease |
|---|
| A09 | 01 | 1 | ENG | @1 Parkinsonism and Dementia: Synucleinopathies, Tauopathies, and Beyond. Proceedings of the "Movement" Disorder Society-European Division-Sponsored Workshop, Istanbul, Turkey, 9-11 May 2002 |
|---|
| A11 | 01 | 1 | | @1 POEWE (Werner) |
|---|
| A14 | 01 | | | @1 Department of Neurology, University of Innsbruck @2 Innsbruck @3 AUT @Z 1 aut. |
|---|
| A18 | 01 | 1 | | @1 "Movement" Disorder Society. European Division @2 Milwaukee, Wisconsin @3 USA @9 patr. |
|---|
| A20 | | | | @2 S80-S87 |
|---|
| A21 | | | | @1 2003 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000113058290110 |
|---|
| A44 | | | | @0 0000 @1 © 2004 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 62 ref. |
|---|
| A47 | 01 | 1 | | @0 04-0080436 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia. |
|---|
| C02 | 01 | X | | @0 002B17G |
|---|
| C03 | 01 | X | FRE | @0 Parkinson maladie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Parkinson disease @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Parkinson enfermedad @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Psychose @5 04 |
|---|
| C03 | 02 | X | ENG | @0 Psychosis @5 04 |
|---|
| C03 | 02 | X | SPA | @0 Psicosis @5 04 |
|---|
| C03 | 03 | X | FRE | @0 Neuroleptique @5 07 |
|---|
| C03 | 03 | X | ENG | @0 Neuroleptic @5 07 |
|---|
| C03 | 03 | X | SPA | @0 Neuroléptico @5 07 |
|---|
| C03 | 04 | X | FRE | @0 Article synthèse @5 16 |
|---|
| C03 | 04 | X | ENG | @0 Review @5 16 |
|---|
| C03 | 04 | X | SPA | @0 Artículo síntesis @5 16 |
|---|
| C03 | 05 | X | FRE | @0 Prévalence @5 17 |
|---|
| C03 | 05 | X | ENG | @0 Prevalence @5 17 |
|---|
| C03 | 05 | X | SPA | @0 Prevalencia @5 17 |
|---|
| C03 | 06 | X | FRE | @0 Symptomatologie @5 18 |
|---|
| C03 | 06 | X | ENG | @0 Symptomatology @5 18 |
|---|
| C03 | 06 | X | SPA | @0 Sintomatología @5 18 |
|---|
| C03 | 07 | X | FRE | @0 Traitement @5 19 |
|---|
| C03 | 07 | X | ENG | @0 Treatment @5 19 |
|---|
| C03 | 07 | X | SPA | @0 Tratamiento @5 19 |
|---|
| C03 | 08 | X | FRE | @0 Homme @5 20 |
|---|
| C03 | 08 | X | ENG | @0 Human @5 20 |
|---|
| C03 | 08 | X | SPA | @0 Hombre @5 20 |
|---|
| C03 | 09 | X | FRE | @0 Chimiothérapie @5 23 |
|---|
| C03 | 09 | X | ENG | @0 Chemotherapy @5 23 |
|---|
| C03 | 09 | X | SPA | @0 Quimioterapia @5 23 |
|---|
| C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
|---|
| C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
|---|
| C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
|---|
| C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
|---|
| C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
|---|
| C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
|---|
| C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
|---|
| C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
|---|
| C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
|---|
| C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
|---|
| C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
|---|
| C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
|---|
| C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
|---|
| N21 | | | | @1 054 |
|---|
| N82 | | | | @1 PSI |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Parkinsonism and Dementia: Sinucleinopathies, Tauopathies, and Beyond. Workshop @3 Istanbul TUR @4 2002-05-09 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002382
Links to Exploration step
Pascal:04-0080436
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Psychosis in Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0080436</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0080436 INIST</idno>
<idno type="RBID">Pascal:04-0080436</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002382</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000939</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Psychosis in Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Human</term>
<term>Neuroleptic</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Psychosis</term>
<term>Review</term>
<term>Symptomatology</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Psychose</term>
<term>Neuroleptique</term>
<term>Article synthèse</term>
<term>Prévalence</term>
<term>Symptomatologie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
</keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords><front><div type="abstract" xml:lang="en">Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA06><s2>6</s2>
<s3>SUP</s3>
</fA06><fA08 i1="01" i2="1" l="ENG"><s1>Psychosis in Parkinson's disease</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>Parkinsonism and Dementia: Synucleinopathies, Tauopathies, and Beyond. Proceedings of the "Movement" Disorder Society-European Division-Sponsored Workshop, Istanbul, Turkey, 9-11 May 2002</s1>
</fA09><fA11 i1="01" i2="1"><s1>POEWE (Werner)</s1>
</fA11><fA14 i1="01"><s1>Department of Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</fA14><fA18 i1="01" i2="1"><s1>"Movement" Disorder Society. European Division</s1>
<s2>Milwaukee, Wisconsin</s2>
<s3>USA</s3>
<s9>patr.</s9>
</fA18><fA20><s2>S80-S87</s2>
</fA20><fA21><s1>2003</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113058290110</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>62 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>04-0080436</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia.</s0>
</fC01><fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Psychose</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>07</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>07</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>07</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>16</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Review</s0>
<s5>16</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>16</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>17</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>17</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Symptomatologie</s0>
<s5>18</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Symptomatology</s0>
<s5>18</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Sintomatología</s0>
<s5>18</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>19</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>19</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>19</s5>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>23</s5>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>23</s5>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>23</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07><fN21><s1>054</s1>
</fN21><fN82><s1>PSI</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Parkinsonism and Dementia: Sinucleinopathies, Tauopathies, and Beyond. Workshop</s1>
<s3>Istanbul TUR</s3>
<s4>2002-05-09</s4>
</fA30>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:04-0080436
|texte= Psychosis in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
